Icosavax, Inc. is a biopharmaceutical company that develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12 targets respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). The company also develops IVX-121 and IVX-241, both vaccine candidates for RSV and hMPV. Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington.

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.

COM:ICOSAVAX

Icosavax, Inc.

Last Close

15.45

16/02 21:00

Market Cap

769.04M

Beta: -

Volume Today

8.56M

Avg: -

Analysis Not Available